Bone health in Parkinson's disease: a comprehensive review of bone involvement and its pathophysiological mechanisms.

Fiche publication

Date publication

janvier 2026

Journal

Frontiers in medicine

Auteurs

Membres identifiés du Cancéropôle Est :
Pr TOUSSIROT Eric

Tous les auteurs :
Toussirot E, Compagne C, Vauchy C, Bereau M

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/41608422

Résumé

Parkinson's disease (PD) is a frequent neurodegenerative disorder that combines motor and non-motor features, including impaired balance, gait disturbances, and progressive loss of mobility. Bone involvement is well established, with low bone mass and elevated fracture risk- especially hip fractures- being common findings. Because of impaired balance, gait disturbances, cognitive dysfunction, and autonomic failure, individuals with PD experience a markedly elevated risk of falls. Osteoporosis in PD likely results from a convergence of nutritional deficiencies, vitamin D insufficiency, weight loss with sarcopenia, and progressive muscle weakness. Anti-Parkinson medications such as levodopa may also contribute through hyperhomocysteinemia. In addition, dopamine depletion and chronic inflammation may further disrupt bone remodeling. This review summarizes current evidence on bone mineral density, bone quality, falls, and fractures in PD and discusses the pathophysiological mechanisms underlying this comorbidity.